FK506治疗肾炎与生化指标的三维图像分析

Treatment of Nephritis with FK506 and 3D Image Analysis of Biochemical Indexes

观察新型免疫抑制剂FK506（普乐可复）对狼疮性肾炎（IV＋V）的疗效与体内血糖、白蛋白、血红蛋白、红细胞、年龄、血钾、血钠指标的关系。针对在我院临床诊断为肾病综合征、病理诊断为狼疮性肾炎（IV＋V）的患者，应用普乐可复（口服剂量9．15～0．3mg／kg／d 2／日）进行治疗。对其血药浓度进行检测，根据血药浓度调整剂量。治疗后患者24小时尿蛋白转阴。新型免疫抑制剂普乐可复有望成为狼疮性肾炎治疗的安全、有效的方法之一。

In order to investigate the correlation between curative effect of tacrolimus on the lupus nephritis （IV＋V） and glucose, albumin, hemoglobin, erythrocyte age, K and Na within patients body, the patients clinically diagnosed as nephritic syndrome and those diagnosed in pathology as lupus nephritis （IV＋V） were treated with tacrolimus （oral dosage 0. 15-0.30mg/ kg/d, twice per day）, and the blood drug level of tacrolimus was monitored and the dosage of it is adjusted accordingly. The results show that the novel immunodepressant trcrolimus is a safe and effective therapy for nephritis （IV＋V）.